Latest Innovation News

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Harvey Norman Holdings detailed its expansive international growth and omni-channel strategy at its 2025 AGM, highlighting new flagship stores and AI-driven retail innovations across eight countries.

Select Harvests Limited delivered a robust FY2025 with net profit soaring to $31.8 million and net debt slashed by over 50%, despite a smaller almond crop. Strategic investments in processing and sales underpin a confident outlook.

Syntara Limited has successfully completed Phase 1a trials for its topical anti-fibrotic drug SNT-9465, demonstrating dose-dependent target engagement and safety, and is now progressing to an innovative Phase 1b study in hypertrophic scars.

Nimy Resources has partnered with CSIRO under the Kick-Start program to advance gallium exploration at its Mons Project in Western Australia, leveraging cutting-edge machine learning and scientific expertise.

Synertec has secured a pivotal contract to supply its zero-emission Powerhouse system to Shell QGC’s Coal Seam Gas operations in Queensland, marking a significant step in industrial decarbonisation.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

CSIRO has sold about half its shares in Chrysos Corporation through a block trade, reducing its stake by roughly 9%, yet remains a committed substantial shareholder with a six-month escrow on its retained shares.

Straker Ltd’s H1 FY26 results reveal a strategic shift from legacy translation services to AI-driven specialised language models, anchored by a $28 million partnership with IBM. Despite a 15% revenue decline, the company maintains positive adjusted EBITDA and a strong balance sheet.

Straker Ltd reports a solid first half of FY26 with positive EBITDA and a renewed IBM partnership, despite a 15% revenue decline amid challenging market conditions.